Global Lung Transplant Therapeutics Market is Growing with a CAGR of 4.8% in the Forecast Period of 2022 to 2029

The Global Lung Transplant Therapeutics Market is growing with factors such as increasing research and development investment for drug discovery and development of immunosuppressant drugs, steroids, rise in chronic lung associated disease, growth in biologics, among others. A rise in expenditure has also given a boom to the global lung transplant therapeutics market.

However, the factors such as the rise in the cost of the lung transplant procedure and the risk associated with transplant surgery may hamper the growth of the global lung transplant therapeutics market.

Global Lung Transplant Therapeutics Market Scenario  

According to Data Bridge Market Research, the market for global lung transplant therapeutic in North America has the highest market share, followed by Europe and Asia-Pacific. The market leader is Astellas Pharma Inc., which accounts for an estimated market share of approximately 31.17% in the global market. The company has gained outstanding sales by providing effective medications for lung transplant operations.

For instance,

  • In April 2021, Astellas Pharma Inc. received the "2021 Award for Excellence in Corporate Disclosure" from the Securities Analysts Association of Japan. This has helped the company in strengthening its position over the market and gaining more customer base

Lung Transplant Therapeutics MarketTrends Impacting the Market

Now the question is which other regions are Astellas Pharma Inc., Transmedics Inc., and Dr. Reddy's Laboratories Ltd targeting? Data Bridge Market Research has forecasted a large growth in the North America lung transplantation therapeutics market and the market leaders targeting Europe and Asia-Pacific to be their next pocket revenue for 2022.

The global lung transplantation therapeutics market is becoming more competitive with companies like Astellas Pharma Inc., Transmedics Inc., and Dr. Reddy's Laboratories Ltd. These are the top dominating companies in the global lung transplantation therapeutics market and has provided a wide variety of services in the market. The data bridge market research new reports highlight the major growth factors and opportunities in the global lung transplantation therapeutics market.

For more analysis on the global lung transplant therapeutics market, request a briefing with our analysts- https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-lung-transplant-therapeutics-market

Global Lung Transplant Therapeutics Market Developments

  • In July 2021, TransMedics obtained the FDA approval for the OCS Lung Solution used for the cold preservation of lungs. The FDA approval received would result in improvement in product portfolio or organ preservation, and it would meet the unmet clinical needs of the organ transplant market. It would ensure collaborations with market players to supply and meet the customer's needs for lung transplantation
  • In January 2022, Hikma Pharmaceuticals PLC expanded in Canada with the acquisition of Teligent sterile injectable assets, which includes a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products, and a pipeline of seven additional products, four of which are approved by Health Canada. This portfolio of exciting products will enable the company to expand North American business and develop a solid position in this important market

Scope of the Global Lung Transplant Therapeutics Market

The global lung transplant therapeutics market is segmented on the basis of countries into the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East and Africa.

All country-based analysis of the global lung transplant therapeutics market is further analyzed based on maximum granularity into further segmentation. On the basis of product, the global lung transplant therapeutics market is segmented into immunosuppressant drugs, tissue products, organ preservation products, and others. On the basis of indication, the global lung transplant therapeutics market is segmented into chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, septic lung disease, pulmonary hypertension, cystic fibrosis, interstitial pulmonary fibrosis, emphysema, primary pulmonary arterial hypertension sarcoidosis, and others. On the basis of type, the global lung transplant therapeutics market is segmented into cadaveric lung transplantation and living lung transplantation. On the basis of technique, the global lung transplant therapeutics market is segmented into single-lung transplantation, bilateral-lung transplantation, heart-lung transplantation, and double lung transplantation. On the basis of patient demographics, the global lung transplant therapeutics market is segmented into an adult, pediatric, and geriatric. On the basis of end users, the global lung transplant therapeutics market is segmented into hospitals, transplant centers, specialty centers, and others.

To know more about the study- https://www.databridgemarketresearch.com/reports/global-lung-transplant-therapeutics-market

Key Pointers Covered in Global Lung Transplant Therapeutics Market Industry Trends and Forecast to 2029

  • Market size
  • Top to bottom market analysis
  • Recent developments for market competitors
  • Recent market value for different countries
  • Market value and overview of lung transplant therapeutics market
  • Company profiling of top eight players of lung transplant therapeutics market

Key Market Competitors Covered in the Report

  • Apotex Inc
  • Bridge to Life Ltd
  • TransMedics (A Subsidiary of TransMedics Group, Inc)
  • Intas Pharmaceuticals Ltd.
  • Viatris Inc.
  • BioLife Solutions
  • Paragonix Technologies, Inc 
  • Ose-immuno
  • XVIVO
  • 21st Century Medicine
  • Pfizer Inc.
  • F.Hoffmann-La Roche Ltd.
  • Panacea Biotec Ltd.
  • Astellas Pharma Inc.
  • Accord-UK Ltd
  • Novartis AG
  • Hikma Pharmaceuticals PLC
  • Dr. Franz Köhler Chemie GmbH
  • Detraxi Inc
  • Dr. Reddy's Laboratories Ltd.

Above are the key players covered in the report. To know about more and exhaustive list of medicines in lung transplant therapeutics, contact us- https://www.databridgemarketresearch.com/toc/?dbmr=global-lung-transplant-therapeutics-market

Research Methodology: Global Lung Transplant Therapeutics Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or can drop down your inquiry.

The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market timeline analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis, and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

  • Demand Side: Manufacturer, Geneticists, Healthcare Industry, Scientists, Research Laboratories
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers, among others

Related Reports

Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/